The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISH 2022 | PETHEMA LAL19: continuation therapy or allogeneic transplantation according to MRD & genetics in ALL
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, comments on the ongoing B-cell precursor acute lymphoblastic leukemia (B-ALL) PETHEMA LAL 19 trial (NCT04179929), its design, future interventions, and its first results. Patient groups were treated according to MRD analysis and the genetic background of the disease, with the design taking into consideration two different approaches as post-consolidation therapy. This interview took place at the 38th World Congress of the International Society of Hematology 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
